The National Heart, Lung, and Blood Institute has tapped NuGen Technologies to provide automated reagent solutions for expression profiling of approximately 6,000 blood samples from the landmark Framingham Heart Study, NuGen said this week.
NuGen's products will be used for an initiative that the Framingham Heart Study launched last year called the Systems Approach to Biomarker Research in Cardiovascular Disease, or SABRe CVD.
Framingham investigators will use NuGEN's Ovation Pico WTA System and Encore Biotin Module One products for a project within the SABRe CVD initiative that aims to use microarrays to "further dissect the genetic risk factors associated with various diseases," NuGen said.
"In the past, much of this genomic information has been inaccessible because the reagent solutions and analytical tools have not been available, have not had sufficient throughput or have been inconsistent in performance," Doug Amorese, vice president of research and development at NuGEN, said in a statement. "With NuGEN's sample preparation solutions, researchers can now explore samples in large repositories with confidence and further develop associations between disease states and genomic markers."